Baidu
map

静脉输液港植入与管理多学科专家共识(2023版)

2023-06-29 中国普通外科杂志 发表于上海

内容涵盖了静脉输液港的植入和维护全部流程,目标是减少植入和使用的并发症,提高使用静脉输液港患者的安全性和满意度。

中文标题:

静脉输液港植入与管理多学科专家共识(2023版)

发布机构:

发布日期:

2023-06-29

简要介绍:

完全植入式静脉给药装置(TIVAD) 又称静脉输液港,是一种新兴的中心静脉输液通路装置,主要应用于肿瘤化疗、肠外营养支持,近年来的应用证实该技术可靠有效。目前国内对该技术的应用主要集中于大型医疗机构,不同地区植入手术和维护存在较大差异,造成实际应用效果差异较大、相关并发症的发生率高、患者满意度差别大。专家组集合了在静脉输液港工作方面具有丰富经验的来自不同专业的多位专家,结合最新研究结果,充分讨论制定了《静脉输液港植入与管理多学科专家共识(2023 版)》,适用于从事静脉输液港工作的医护人员,内容涵盖了静脉输液港的植入和维护全部流程,目标是减少植入和使用的并发症,提高使用静脉输液港患者的安全性和满意度。
 

相关资料下载:
[AttachmentFileName(sort=1, fileName=静脉输液港植入与管理多学科专家共识(2023版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=0ceea1c0032356c3, title=静脉输液港植入与管理多学科专家共识(2023版), enTitle=, guiderFrom= 中国普通外科杂志, authorId=0, author=, summary=内容涵盖了静脉输液港的植入和维护全部流程,目标是减少植入和使用的并发症,提高使用静脉输液港患者的安全性和满意度。, cover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Jun 29 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;">完全植入式静脉给药装置(TIVAD) 又称静脉输液港,是一种新兴的中心静脉输液通路装置,主要应用于肿瘤化疗、肠外营养支持,近年来的应用证实该技术可靠有效。目前国内对该技术的应用主要集中于大型医疗机构,不同地区植入手术和维护存在较大差异,造成实际应用效果差异较大、相关并发症的发生率高、患者满意度差别大。专家组集合了在静脉输液港工作方面具有丰富经验的来自不同专业的多位专家,结合最新研究结果,充分讨论制定了《静脉输液港植入与管理多学科专家共识(2023 版)》,适用于从事静脉输液港工作的医护人员,内容涵盖了静脉输液港的植入和维护全部流程,目标是减少植入和使用的并发症,提高使用静脉输液港患者的安全性和满意度。</div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/29242">&nbsp;</div> </div>, tagList=[TagDto(tagId=75960, tagName=静脉输液港)], categoryList=[CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=75960, articleKeyword=静脉输液港, articleKeywordNum=6, guiderKeywordId=75960, guiderKeyword=静脉输液港, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8500, appHits=161, showAppHits=0, pcHits=735, showPcHits=8339, likes=1, shares=24, comments=3, approvalStatus=1, publishedTime=Tue Jul 11 16:34:12 CST 2023, publishedTimeString=2023-06-29, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Jul 11 16:35:12 CST 2023, updatedBy=8538692, updatedName=风湿免疫小助手, updatedTime=Sat Jan 06 08:08:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=静脉输液港植入与管理多学科专家共识(2023版).pdf)])
静脉输液港植入与管理多学科专家共识(2023版).pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2220147, encodeId=ab44222014e6c, content=我们应当持续改进自身的不足之处,充分发挥我们的优势,以此来取得更大的成就。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be19423285, createdName=ms2000001493866103, createdTime=Wed Aug 14 20:43:09 CST 2024, time=2024-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2153227, encodeId=fe8e215322eee, content=有了指南共识工作有依据了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eff5597433, createdName=ms4000000760303785, createdTime=Thu Aug 17 13:47:43 CST 2023, time=2023-08-17, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147785, encodeId=848f214e7856d, content=有了规范化指南,以后更好的操作了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Thu Jul 13 08:22:07 CST 2023, time=2023-07-13, status=1, ipAttribution=内蒙古)]
    2024-08-14 ms2000001493866103 来自广东省

    我们应当持续改进自身的不足之处,充分发挥我们的优势,以此来取得更大的成就。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2220147, encodeId=ab44222014e6c, content=我们应当持续改进自身的不足之处,充分发挥我们的优势,以此来取得更大的成就。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be19423285, createdName=ms2000001493866103, createdTime=Wed Aug 14 20:43:09 CST 2024, time=2024-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2153227, encodeId=fe8e215322eee, content=有了指南共识工作有依据了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eff5597433, createdName=ms4000000760303785, createdTime=Thu Aug 17 13:47:43 CST 2023, time=2023-08-17, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147785, encodeId=848f214e7856d, content=有了规范化指南,以后更好的操作了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Thu Jul 13 08:22:07 CST 2023, time=2023-07-13, status=1, ipAttribution=内蒙古)]
    2023-08-17 ms4000000760303785 来自山东省

    有了指南共识工作有依据了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2220147, encodeId=ab44222014e6c, content=我们应当持续改进自身的不足之处,充分发挥我们的优势,以此来取得更大的成就。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be19423285, createdName=ms2000001493866103, createdTime=Wed Aug 14 20:43:09 CST 2024, time=2024-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2153227, encodeId=fe8e215322eee, content=有了指南共识工作有依据了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eff5597433, createdName=ms4000000760303785, createdTime=Thu Aug 17 13:47:43 CST 2023, time=2023-08-17, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2147785, encodeId=848f214e7856d, content=有了规范化指南,以后更好的操作了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Thu Jul 13 08:22:07 CST 2023, time=2023-07-13, status=1, ipAttribution=内蒙古)]
    2023-07-13 豪杰克 来自内蒙古

    有了规范化指南,以后更好的操作了

    0

拓展阅读

植入式静脉输液港相关感染,该如何防控?

我们知道植入式静脉输液港(implantable venous access port,IVAP,简称PORT)是一种可供反复穿刺的全植入式血管通道装置,自1982年应用于临床以来,在肿瘤患者静脉化疗等领域得到广泛应用。

Baidu
map
Baidu
map
Baidu
map